Key terms
About SWTX
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SWTX news
Mar 06
6:40am ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
Mar 06
6:08am ET
SpringWorks Therapeutics price target raised to $74 from $73 at JPMorgan
Mar 04
6:40am ET
SpringWorks Therapeutics submits rolling NDA to FDA for mirdametinib
Mar 01
12:15am ET
3 Best Stocks to Buy Now, 3/1/2024, According to Top Analysts
Feb 29
8:41am ET
SpringWorks Therapeutics announces EMA validaion for nirogacestat MAA
Feb 29
6:44am ET
SpringWorks Therapeutics price target raised to $63 from $47 at Barclays
Feb 29
6:30am ET
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Springworks Therapeutics (SWTX)
Feb 28
5:50am ET
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)
Feb 28
5:50am ET
Springworks Therapeutics: A Buy Rating on Ogsiveo’s Success and Promising Pipeline
Feb 27
5:19pm ET
SpringWorks Therapeutics price target raised to $59 from $54 at Goldman Sachs
Feb 27
10:35am ET
Springworks Therapeutics: A Strong Buy on Ogsiveo’s Market Triumph and Growth Potential
Feb 27
10:30am ET
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX) and ACADIA Pharmaceuticals (ACAD)
Feb 27
10:20am ET
Analysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)
Feb 27
6:33am ET
SpringWorks Therapeutics reports Q4 EPS ($1.44), consensus ($1.24)
Feb 26
8:00am ET
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Feb 26
7:43am ET
SpringWorks Therapeutics price target raised to $70 from $60 at Wedbush
Feb 26
6:19am ET
Goldman Sachs Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
Jan 25
5:40am ET
SpringWorks Therapeutics price target raised to $47 from $41 at Barclays
Jan 25
5:35am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 18
1:13am ET
3 Best Stocks to Buy Now, 1/18/2024, According to Top Analysts
Jan 17
7:40am ET
JPMorgan ups SpringWorks target, adds to Analyst Focus List
Dec 08
3:45pm ET
Buy Rating Justified: Springworks Therapeutics’s Ogsiveo Poised to Transform Desmoid Tumor Treatment
Dec 08
11:18am ET
Goldman Sachs pharmaceuticals analysts hold an analyst/industry conference call
SWTX Financials
Key terms
Ad Feedback
SWTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SWTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
